Table 2. Pre- and post-doxycycline functional parameters, matrix metalloproteinase levels, VEGF-D levels, and Medical Outcomes Study 36-item Short-form Health Survey scores in the 13 lymphangioleiomyomatosis patients allocated to the doxycycline-responder groupa on the basis of their response to doxycycline (as determined by the variation in FEV1). b .
| Variable | Doxy-R group | p | ||
| Pre-doxycycline | Post-doxycycline | |||
| Pulmonary function test | ||||
| FVC, L | 3.0 ± 0.3 | 3.2 ± 0.3 | 0.023 | |
| FVC, % of predicted | 90 ± 13 | 95 ± 12 | 0.026 | |
| FEV1, L | 2.31 ± 0.40 | 2.40 ± 0.40 | 0.003 | |
| FEV1, % of predicted | 84 ± 14 | 86 ± 14 | 0.002 | |
| FEV1/FVC ratio | 0.77 ± 0.10 | 0.76 ± 0.10 | 0.173 | |
| TLC, L | 4.6 ± 0.5 | 4.8 ± 0.6 | 0.310 | |
| TLC, % of predicted | 98 ± 13 | 101 ± 15 | 0.327 | |
| RV, L | 1.6 ± 0.5 | 1.6 ± 0.6 | 0.956 | |
| RV, % of predicted | 117 ± 43 | 118 ± 47 | 0.940 | |
| RV/TLC ratio | 0.34 ± 0.08 | 0.33 ± 0.08 | 0.640 | |
| DLCO, mL/min/mmHg | 18.5 ± 6.0 | 18.0 ± 5.0 | 0.514 | |
| DLCO, % of predicted | 72 ± 20 | 70 ± 18 | 0.448 | |
| Six-minute walk test | ||||
| Distance, m | 515 ± 66 | 523 ± 52 | 0.633 | |
| Minimum SpO2, % c | 94 (93-95) | 94 (91-95) | 0.500 | |
| Biomarkers c | ||||
| Serum MMP-9, ng/mL | 837 (716-1,033) | 1,103 (773-1,237) | 0.328 | |
| Urinary MMP-9, pg/mL | 8,905 (5,607-21,829) | 6,735 (674-8,983) | 0.050 | |
| Serum MMP-2, pg/mL | 0 (0-182) | 0 (0-40) | 0.144 | |
| VEGF-D, pg/mL | 413 (277-2,113) | 328 (257-2,008) | 0.374 | |
| SF-36 domains c | ||||
| Physical functioning | 75 (65-85) | 80 (75-95) | 0.281 | |
| Role-physical | 50 (50-50) | 100 (50-100) | 0.020 | |
| Bodily pain | 57.5 (55-90) | 70 (55-77.5) | 1.000 | |
| General health | 80 (45-90) | 75 (70-85) | 0.412 | |
| Vitality | 70 (45-90) | 70 (70-85) | 0.428 | |
| Role-emotional | 33 (33-100) | 100 (33-100) | 0.158 | |
| Mental health | 68 (40-84) | 76 (52-88) | 0.051 | |
| Social functioning | 75.0 (50.0-88.5) | 87.5 (62.5-100) | 0.040 |
Doxy-R group: : doxycycline-responder group; minimum SpO2: minimum SpO2 sustained for 10 s;
MMP
: matrix metalloproteinase;
SF-36: : Medical Outcomes Study 36-item Short-form Health Survey.
a
Group of patients who responded to treatment with doxycycline, as evidenced by increased or stable FEV1 at doxycycline treatment month 12 in comparison with FEV1 at baseline.
b
Values expressed as mean ± SD, except where otherwise indicated.
c
Values expressed as median (interquartile range).